The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2013 Apr 18

PMID 23591839

Citations 91

Authors

Zachary C Dobbin

Charles N Landen

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is the fifth most common cause of death due to cancer in women despite being the tenth in incidence. Unfortunately, the five-year survival rate is only 45%, which has not improved much in the past 30 years. Even though the majority of women have successful initial therapy, the low rate of survival is due to the eventual recurrence and succumbing to their disease. With the recent release of the Cancer Genome Atlas for ovarian cancer, it was shown that the PI3K/AKT/mTOR pathway was one of the most frequently mutated or altered pathways in patients' tumors. Researching how the PI3K/AKT/mTOR pathway affects the progression and tumorigensis of ovarian cancer will hopefully lead to new therapies that will increase survival for women. This review focuses on recent research on the PI3K/AKT/mTOR pathway and its role in the progression and tumorigensis of ovarian cancer.

Citing Articles

Investigation of the mechanism by which FOXJ2 inhibits proliferation, metastasis and cell cycle progression of ovarian cancer cells through the PI3K/AKT signaling pathway.

Wang L, He H, Zhai R, Gao R, Su M, Duan R Eur J Med Res. 2025; 30(1):152.

PMID: 40038842 PMC: 11881463. DOI: 10.1186/s40001-025-02270-7.

Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines.

Almeida-Nunes D, Silva J, Nunes M, Silva P, Silvestre R, Dinis-Oliveira R Int J Mol Sci. 2024; 25(22).

PMID: 39596005 PMC: 11594113. DOI: 10.3390/ijms252211935.

The apoptotic and anti-proliferative effects of Neosetophomone B in T-cell acute lymphoblastic leukaemia via PI3K/AKT/mTOR pathway inhibition.

Kuttikrishnan S, Ansari A, Suleman M, Ahmad F, Prabhu K, El-Elimat T Cell Prolif. 2024; 58(3):e13773.

PMID: 39542458 PMC: 11882758. DOI: 10.1111/cpr.13773.

Exploring the therapeutic mechanisms of Yikang decoction in polycystic ovary syndrome: an integration of GEO datasets, network pharmacology, and molecular dynamics simulations.

Miao J, Gao L, Liu X, Cai W, Chen L, Chen M Front Med (Lausanne). 2024; 11:1455964.

PMID: 39421869 PMC: 11484630. DOI: 10.3389/fmed.2024.1455964.

PIM Kinase Inhibitors as Novel Promising Therapeutic Scaffolds in Cancer Therapy.

Karati D, Saha A, Roy S, Mukherjee S Curr Top Med Chem. 2024; 24(28):2489-2508.

PMID: 39297470 DOI: 10.2174/0115680266321659240906114742.

References

Markman B, Dienstmann R, Tabernero J . Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 2011; 1(7):530-543. PMC: 3248125. DOI: 10.18632/oncotarget.188. View

Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K . Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res. 2011; 71(13):4720-31. PMC: 3129420. DOI: 10.1158/0008-5472.CAN-11-0365. View

Brew K, Dinakarpandian D, Nagase H . Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477(1-2):267-83. DOI: 10.1016/s0167-4838(99)00279-4. View

Kinross K, Montgomery K, Kleinschmidt M, Waring P, Ivetac I, Tikoo A . An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest. 2012; 122(2):553-7. PMC: 3266789. DOI: 10.1172/JCI59309. View

Altomare D, Wang H, Skele K, De Rienzo A, Klein-Szanto A, Godwin A . AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004; 23(34):5853-7. DOI: 10.1038/sj.onc.1207721. View

Pandey D, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D . Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009; 28(5):523-32. PMC: 2657575. DOI: 10.1038/emboj.2008.304. View

Tomek K, Wagner R, Varga F, Singer C, Karlic H, Grunt T . Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol Cancer Res. 2011; 9(12):1767-79. DOI: 10.1158/1541-7786.MCR-10-0467. View

Curran S, Murray G . Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000; 36(13 Spec No):1621-30. DOI: 10.1016/s0959-8049(00)00156-8. View

Shiromizu K, Mattison D . Murine oocyte destruction following intraovarian treatment with 3-methylcholanthrene or 7,12-dimethylbenz(a)anthracene: protection by alpha-naphthoflavone. Teratog Carcinog Mutagen. 1985; 5(6):463-72. DOI: 10.1002/tcm.1770050609. View

10.

Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

11.

Bellacosa A, De Feo D, Godwin A, BELL D, Cheng J, Altomare D . Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995; 64(4):280-5. DOI: 10.1002/ijc.2910640412. View

12.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

13.

Byun H, Kim B, Yoo R, Park S, Rho S . sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR. Apoptosis. 2012; 17(10):1095-103. DOI: 10.1007/s10495-012-0751-0. View

14.

Kim J, Coffey D, Creighton C, Yu Z, Hawkins S, Matzuk M . High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012; 109(10):3921-6. PMC: 3309733. DOI: 10.1073/pnas.1117135109. View

15.

Armstrong D . Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002; 7 Suppl 5:20-8. DOI: 10.1634/theoncologist.7-suppl_5-20. View

16.

Sobinoff A, Nixon B, Roman S, McLaughlin E . Staying alive: PI3K pathway promotes primordial follicle activation and survival in response to 3MC-induced ovotoxicity. Toxicol Sci. 2012; 128(1):258-71. DOI: 10.1093/toxsci/kfs137. View

17.

McCluggage W . Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-32. DOI: 10.1097/PAT.0b013e328348a6e7. View

18.

Imam J, Plyler J, Bansal H, Prajapati S, Bansal S, Rebeles J . Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One. 2013; 7(12):e52397. PMC: 3528651. DOI: 10.1371/journal.pone.0052397. View

19.

Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V . Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet. 2004; 41(3):161-70. PMC: 1735712. DOI: 10.1136/jmg.2003.015339. View

20.

Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A . G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007; 67(4):1859-66. DOI: 10.1158/0008-5472.CAN-06-2909. View